Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

15. april 2016 opdateret af: Sanofi

A Multicenter, Randomized, Placebo-controlled, "Factorial" Design, 12-month Study to Evaluate the Efficacy and Safety of AVE5530 25 mg/Day and 50 mg/Day Co-administered With All Registered Atorvastatin Strengths Ranging From 10 mg to 80 mg in Patients With Primary Hypercholesterolemia

The present study is assessing the efficacy and safety of AVE5530 (25mg and 50mg) co-administered with all approved doses of atorvastatin in a double-blind comparison with placebo, AVE5530 alone and atorvastatin alone in the management of patients with primary hypercholesterolemia. The main objective is to evaluate the effects of the association AVE5530+atorvastatin on LDL-C level reduction after 12 weeks of treatment. The effects of AVE5530+atorvastatin on other lipid parameters will be assessed as secondary objectives

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

The study will include a 2 week pre-randomization placebo lead-in phase. There will be a 12- week double-blind treatment period for both components AVE5530 and atorvastatin, followed by a 40-week period with maintenance of double-blind design for AVE5530 component and open label for atorvastatin component transitioning at 20 mg for all patients with subsequent titration, if necessary, based on regular LDL-cholesterol monitoring. The treatment period can be variably extended up to approximately 18 months with double-blind for AVE5530 component and open-label for atorvastatin.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

1736

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New Jersey
      • Bridgewater, New Jersey, Forenede Stater, 08807
        • Sanofi-Aventis Administrative Office
      • Puerto Rico, Puerto Rico
        • Sanofi-Aventis Administrative Office

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adults with high cholesterol levels either not receiving or willing and able to discontinue ongoing lipid-lowering therapy

Exclusion Criteria:

  • LDL-C levels > 250 mg/dL (6.48 mmol/L)
  • Triglycerides levels > 350mg/dL (3.95 mmol/L)
  • Conditions / situations such as:

    • presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels
    • Active liver disease
    • High estimated risk of Coronary Heart Disease
    • Recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease
    • Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive
  • Pregnant or breast-feeding women,
  • Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product
  • Hypersensitivity to any component of atorvastatin
  • Concurrent administration of Cytochrome P450 3A4 inhibitors (e.g. cyclosporine, erythromycin, clarithromycin, and azole antifungals) should be avoided as increasing the risk of myopathy with atorvastatin

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Faktoriel opgave
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: 1
oral administration once daily in the evening with dinner
Eksperimentel: 2
AVE5530 25mg
oral administration once daily in the evening with dinner
Eksperimentel: 3
AVE5530 50mg
oral administration once daily in the evening with dinner
Aktiv komparator: 4
atorvastatin 10mg
oral administration once daily in the evening with dinner
Eksperimentel: 5
atorvastatin 10mg + AVE5530 25mg
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
Eksperimentel: 6
atorvastatin 10mg + AVE5530 50mg
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
Aktiv komparator: 7
atorvastatin 20mg
oral administration once daily in the evening with dinner
Eksperimentel: 8
atorvastatin 20mg + AVE5530 25mg
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
Eksperimentel: 9
atorvastatin 20mg + AVE5530 50mg
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
Aktiv komparator: 10
atorvastatin 40mg
oral administration once daily in the evening with dinner
Eksperimentel: 11
atorvastatin 40mg + AVE5530 25mg
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
Eksperimentel: 12
atorvastatin 40mg + AVE5530 50mg
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
Aktiv komparator: 13
atorvastatin 80mg
oral administration once daily in the evening with dinner
Eksperimentel: 14
atorvastatin 80mg + AVE5530 25mg
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
Eksperimentel: 15
atorvastatin 80mg + AVE5530 50mg
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Procentvis ændring fra baseline i beregnet LDL-C
Tidsramme: I uge 12
I uge 12

Sekundære resultatmål

Resultatmål
Tidsramme
Procentvis ændring fra baseline i beregnet LDL-C
Tidsramme: Ved 6 måneder og 12 måneder
Ved 6 måneder og 12 måneder
Percent change from baseline in total cholesterol, HDL-C, TG, Apo-A1, Apo-B and CRP
Tidsramme: At week 12, 6 months and 12 months
At week 12, 6 months and 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Davidson Michael, MD, Radiant Research - 515 North State Street Suite 2700 Chicago Illinois (US)

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. august 2008

Primær færdiggørelse (Faktiske)

1. maj 2009

Studieafslutning (Faktiske)

1. juni 2009

Datoer for studieregistrering

Først indsendt

25. august 2008

Først indsendt, der opfyldte QC-kriterier

25. august 2008

Først opslået (Skøn)

26. august 2008

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

16. maj 2016

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. april 2016

Sidst verificeret

1. april 2016

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner